Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049478 | 0.90 | MAPT (0.37) | MAPTSMN1; SMN2POLBGPR119TLR7 | |
| SCHEMBL5041476 | 0.85 | MAPT (0.43) | MAPTSMN1; SMN2POLBGPR119TLR7 | |
| SCHEMBL5042047 | 0.83 | TLR7 (0.37) | MAPTSMN1; SMN2POLBGPR119TLR7 | |
| SCHEMBL5044889 | 0.83 | TLR7 (0.43) | MAPTSMN1; SMN2POLBGPR119TLR7 | |
| SCHEMBL5045844 | 0.83 | ESR1 (0.48) | MAPTSMN1; SMN2GPR119HDAC6ESR1 | |
| SCHEMBL14095569 | 0.82 | MAPT (0.41) | MAPTSMN1; SMN2POLBGPR119TLR7 | |
| SCHEMBL5050052 | 0.81 | TLR7 (0.37) | MAPTSMN1; SMN2POLBGPR119TLR7 | |
| SCHEMBL5045097 | 0.78 | KDM4E (0.47) | MAPTSMN1; SMN2POLB | |
| SCHEMBL5049477 | 0.74 | MAPT (0.42) | MAPTSMN1; SMN2POLBGPR119TLR7 | |
| SCHEMBL5042502 | 0.68 | TLR7 (0.39) | MAPTSMN1; SMN2POLBGPR119TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414138-B2 | Benzoxazole and benzodiazole UV-A sunscreens | DSM IP ASSETS B.V. (NL) | 2008-08-19 | — | — | US | disclosed |
| US-20050260144-A1 | Benzoxazole and benzodiazole uv-a sunscreens | DSM IP ASSETS B.V. (NL) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260144-A1 | Benzoxazole and benzodiazole uv-a sunscreens | SUN2, CYP27B1, ERCC4 | MAPT 543/4885SMN1; SMN2 3995/4885POLB 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.